Genentech: Paul J Fielder | VP PTPK OMNI Biomarker Dev, PTPK & ITGR/OMNI Biomarker Development

Scientists / Our Scientists

"Many Scientists aspire to help discover and develop a life changing therapeutic for a significant unmet medical need. At Genentech, we have had the privilege of helping to make this a reality for thousands of patients. To be a part of this mission is both humbling and inspiring."

Years at Genentech

Publications

Awards & Honors

After completing my Ph.D. at UCSC and Postdoctoral fellowship at Stanford, I joined Genentech in 1993 as a Scientist to help develop a new field studying the Pharmacokinetics and Pharmacodynamics of protein therapeutics. I was drawn to Genentech because of its great scientific reputation and it offered me the best opportunity to pursue great science in the mission of helping patients.

Over my career at Genentech, I have had the privilege of contributing to the discovery and development of multiple therapeutics, as well as, the training and development of our next generation of scientists and drug developers.

Featured Publication

Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins.

Journal of Pharmacology and Experimental Therapeutics. 2008 Nov;327(2):308-15.

Stefanich EG, Ren R, Danilenko DM, Lim A, Song A, Iyer S, Fielder PJ.

View Abstract

The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.

Journal of Clinical Endocrinology & Metabolism. 87(10):4508-14, 2002 Oct.

Cook DM. Biller BM. Vance ML. Hoffman AR. Phillips LS. Ford KM. Benziger DP. Illeperuma A. Blethen SL. Attie KM. Dao LN. Reimann JD. Fielder PJ.

View Abstract

I am currently leading 2 groups focused on Preclinical and Translational Pharmacology for all therapeutic areas and Biomarkers and Diagnostics for our non-oncology pipeline. These groups contribute to the preclinical and clinical development of molecules in multiple therapeutic areas, as well as, to the basic science of Pharmacokinetics, Systems Pharmacology and Biomarkers/Diagnostics.

Together our major goals are to develop state of the art “Translational Pharmacology” and “Biomarker” tools, data, and analyses to help enter the clinical development with both the knowledge and tools to maximize clinical success, to enable informed decision-making, and to enable our PHC mission. Ultimately our data helps ensure we give the right drug at the right dose to the right patients.

Complex formation of anti-VEGF-C with VEGF-C released during blood coagulation resulted in an artifact in its serum pharmacokinetics

Pharmacology Research and Perspectives, ISSN: 20521707

Daniela Bumbaca Yadav; Art Reyes; Priyanka Gupta; Jean-Michel Vernes; Y Gloria Meng; Michelle Schweiger; Shannon Stainton; Germaine Fuh; Paul Fielder; Amrita Kamath; Ben-Quan Shen

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Paul J Fielder

VP PTPK OMNI Biomarker Dev, PTPK & ITGR/OMNI Biomarker Development

Featured Publication

Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins.

The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.

Portraits in Science

The Growth Factor